Compare Crowdstrike Holdings Inc (CRWD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs TransMedics Group Inc — how do they compare? Crowdstrike Holdings Inc trades at $274.17 (market cap $269.31B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Crowdstrike Holdings Inc is far larger — about 98.3× TransMedics Group Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and TransMedics Group Inc for 24 Days on average.
| CRWD | TMDX | |
|---|---|---|
Market Cap | $269.31B | $2.74B |
Volume | 9,381,560 | 949,331 |
Sector | Technology | Health |
52-Week High | $278.86 | $150.42 |
52-Week Low | $87.56 | $61.99 |
Typical Hold Time | 97 Days | 24 Days |
Enterprise Value | $265.11B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $272.00, up 2.47% today and near its all-time highs, with strong technical momentum and bullish moving average signals. The company demonstrates impressive revenue growth, reaching $3.95 billion in 2025, though profitability remains volatile with a net income margin of -0.49%. Recent quarterly earnings have consistently beaten expectations, and analyst sentiment remains overwhelmingly positive with 76% buy ratings.
The outlook for CRWD remains favorable given strong cybersecurity demand and AI-driven growth opportunities, though elevated valuation multiples and competitive pressures present risks. Wall Street's consensus price target of $235.74 suggests potential downside from current levels, but continued execution on revenue growth and margin expansion could support further upside.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
